Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Everolimus first, better outcomes. A phase 2 trial found that treatment sequences beginning with everolimus delivered the longest survival in patients with metastatic clear cell renal cell carcinoma (RCC). The everolimus-then-pazopanib combo topped the charts with a median overall survival of 70.6 months — more than double the worst-performing strategy.
Sequence matters in metastatic kidney cancer treatment
A phase 2 trial called START has shed new light on how the order of treatments — not just which drugs are used — can dramatically affect survival in metastatic clear cell renal cell carcinoma (RCC). Researchers tested six two-drug sequential strategies using everolimus, pazopanib, and bevacizumab across 175 patients, tracking outcomes over a median follow-up of 6.1 years.
The winner? Everolimus followed by pazopanib, which achieved the longest median overall survival (OS) at 70.6 months and the longest time to overall treatment failure at 25.4 months. The worst-performing strategy — bevacizumab followed by pazopanib — posted an OS of just 32.3 months, with more than double the risk of death compared to the top strategy.
By the Numbers
Why it matters: Early response rates can be misleading. This study shows that choosing a treatment sequence based on long-term, "salvage-aware" survival data — rather than short-term tumor shrinkage — could meaningfully extend patients' lives.